|Rexahn Pharmaceuticals, Inc.|
15245 Shady Grove Road
United States - Map
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.
|Dr. Chang H. Ahn Ph.D.,
Founder, Chairman and Chief Scientist
|Dr. Peter D. Suzdak Ph.D.,
Chief Exec. Officer and Director
|Mr. Rakesh Soni ,
Pres and Chief Operating Officer
|Dr. Tae Heum Jeong D. Mgt.,
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
|Dr. Stephen M. Stahl M.D., Ph.D.,
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|